📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
Latest filing: 2026-07-30 14:42
453 analysed today
453
Today
133,342
All-time analysed
40,106
Positive
6,279
Negative
79,144
Neutral
7,745
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
10 announcements match the current filters (relevance ≥ 5).
Rs 32 Dividend and 31% PAT Growth: Ajanta Pharma Reports Strong Q1 FY2027 Results
Ajanta Pharma delivered a robust Q1 FY2027 with revenue rising 25% YoY to Rs 1,626 cr and PAT climbing 31% to Rs 334 cr. The company declared a substantial interim dividend of Rs 32 per share, totaling Rs 400 cr, which represents approximately 38% of its total FY26 net profit. Performance was bolstered by a 57% surge in US Generics and 24% growth in India Branded Generics, although the Asia segment saw a 16% decline. The company maintains high capital efficiency with a 37% ROCE.
Confidence: HIGH
What changedAjanta Pharma has started FY27 with accelerated revenue and profit growth compared to previous years, accompanied by a large interim dividend payout.
Why it mattersThe results demonstrate strong execution in specialty formulations and high cash generation capability, reinforcing the company's ability to maintain high margins and return capital to shareholders.
Interim Dividend: Rs 32 per shareDividend Payout vs FY26 PAT: ~37.8%Q1 Revenue Growth (YoY): 25%US Generics Growth (YoY): 57%ROCE: 37%Record Date: 5th August 2026
📅 Short termThe stock is likely to see positive momentum driven by the earnings beat and the attractive dividend yield ahead of the August 5 record date.
📈 Long termThe company's focus on branded generics in emerging markets and a selective US portfolio supports a sustainable long-term growth trajectory with high capital efficiency.
⚠ Risk flags
- 16% decline in Asia segment revenue
- Potential pricing pressure in US generics
- Forex volatility impacting reported margins
Key Highlights
Declared 1st interim dividend of Rs 32 per share (Face Value Rs 2) with a total outlay of Rs 400 cr.
Q1 FY27 Revenue increased 25% YoY to Rs 1,626 cr, significantly higher than the 3-year CAGR of 14%.
US Generics segment grew 57% YoY to Rs 487 cr, now contributing 30% of total revenue.
India Branded Generics grew 24% to Rs 509 cr, outpacing the Indian Pharma Market (IPM) growth by 36%.
Adjusted EBITDA (excluding forex loss) stood at Rs 454 cr, representing a 28% margin.
👀 What to Watch
Watch for the sustainability of the US segment's high growth and the recovery of the Asia business in upcoming quarters. Note the record date of August 5, 2026, for the Rs 32 dividend eligibility.
Q1 PAT up 31% to ₹334 Cr; ₹32/share Interim Dividend Announced
Ajanta Pharma reported a robust Q1 FY27 with revenue growing 25% YoY to ₹1,626 cr and PAT increasing 31% to ₹334 cr. The board declared a significant interim dividend of ₹32 per share, involving a total payout of ₹400 cr, which is approximately 38% of its total FY26 PAT. Growth was led by a 57% surge in US Generics and 24% growth in India Branded Generics, though the Asia Branded segment saw a 16% decline. Capital efficiency remains high with ROCE improving to 37% from 31% in the previous fiscal.
Confidence: HIGH
What changedThe company reported its Q1 FY27 results showing accelerated growth in the US and India, alongside a large interim dividend payout.
Why it mattersThe results confirm Ajanta's ability to outpace market growth in branded generics and manage US pricing pressure effectively, while maintaining a debt-free, high-ROCE balance sheet.
Revenue (Q1 FY27): ₹1,626 crPAT (Q1 FY27): ₹334 crInterim Dividend: ₹32 per shareDividend Payout vs FY26 PAT: ~37.9%US Generics Growth: 57%ROCE: 37%
📅 Short termThe stock is likely to react positively to the earnings beat and the high dividend yield offered by the ₹32/share payout before the August 5 record date.
📈 Long termAjanta continues to demonstrate a superior branded-generic model with high capital efficiency; long-term value depends on successful new launches in chronic therapies.
⚠ Risk flags
- 16% YoY decline in Asia Branded Generics revenue
- Potential pricing pressure in the US generic market
- Forex volatility impacting margins
Key Highlights
Revenue from operations increased 25% YoY to ₹1,626 cr, driven by US and India markets.
Profit After Tax (PAT) grew 31% YoY to ₹334 cr with a healthy 21% net margin.
Declared 1st interim dividend of ₹32 per share on a face value of ₹2, totaling ₹400 cr.
US Generics revenue grew 57% YoY to ₹487 cr, now contributing 30% of total revenue.
India Branded Generics outperformed the Indian Pharmaceutical Market (IPM) growth by 36%.
👀 What to Watch
Watch for the sustainability of high margins in the US Generics segment and the recovery timeline for the Asia Branded business which contracted 16%. The record date for the ₹32 dividend is August 5, 2026.
Ajanta Pharma Receives US FDA EIR with VAI Status for Paithan Facility
Ajanta Pharma has received the Establishment Inspection Report (EIR) from the US FDA for its Paithan, Maharashtra manufacturing facility. The inspection, conducted from April 13 to April 21, 2026, resulted in a 'Voluntary Action Indicated' (VAI) classification. This status indicates that while some objectionable conditions were found, the agency does not intend to take regulatory action, effectively clearing the facility for ongoing operations and new product approvals. This is significant for the company's US generics strategy, contributing to its TTM revenue of ₹5,453 cr.
Confidence: HIGH
What changedThe US FDA has concluded its audit of the Paithan facility and issued an EIR, transitioning the site from 'under inspection' to 'cleared' status.
Why it mattersRegulatory compliance is critical for pharmaceutical companies to maintain access to the US market. A VAI status ensures no disruption to current exports and allows for the commercialization of new products from this site.
Inspection Start Date: 13 April 2026Inspection End Date: 21 April 2026TTM Revenue: ₹5453 CrOperating Profit Margin: 25.6%Number of Manufacturing Plants: 7
📅 Short termThe news is likely to be viewed positively by the market as it removes regulatory uncertainty regarding one of the company's key manufacturing assets.
📈 Long termConsistent regulatory compliance supports Ajanta's long-term strategy of selective participation in the US generic market while focusing on high-margin branded generics elsewhere.
⚠ Risk flags
- VAI implies minor objectionable conditions were found; failure to maintain compliance in future audits remains a risk.
Key Highlights
Inspection conducted by US FDA from 13 April 2026 to 21 April 2026
Facility at Paithan, Maharashtra received VAI (Voluntary Action Indicated) classification
Ajanta Pharma operates a total of 7 manufacturing plants across India
Company maintains high gross margins of 78% despite generic pricing pressure
TTM revenue stands at ₹5,453 cr with a healthy OPM of 25.6%
👀 What to Watch
Investors should monitor the pace of new ANDA (Abbreviated New Drug Application) approvals from the Paithan facility, as the VAI status removes regulatory hurdles for new launches.
Ajanta Pharma FY26 Revenue Hits ₹5,453 Cr; PAT Crosses ₹1,000 Cr Milestone
Ajanta Pharma delivered a robust performance in FY 2025-26, with revenue growing 17% to ₹5,453 crore and PAT crossing the ₹1,000 crore mark for the first time. The US Generics segment was a major growth driver, surging 49% YoY, while the domestic India business grew 15%, significantly outperforming the broader market. The company maintained high capital efficiency with a 33% RoCE and a 25% RoE, while returning ₹350 crore to shareholders through dividends and buybacks.
Key Highlights
Revenue from operations grew 17% YoY to ₹5,453 crore with a 5-year CAGR of 13%.
Net Profit (PAT) surpassed the ₹1,000 crore milestone, reaching ₹1,056 crore (15% growth).
US Generics business posted exceptional growth of 49% driven by successful new launches.
Maintained strong profitability with an adjusted EBITDA margin of 27% and PAT margin of 19%.
India business grew at 1.3 times the market rate, supported by expansion into new therapies like gynaecology.
👀 What to Watch
Investors should take note of the company's superior capital efficiency (33% RoCE) and its ability to scale the US business profitably. The stock remains a high-quality play in the pharma sector due to its diversified revenue streams and consistent double-digit growth across key markets.
Ajanta Pharma Q4 FY26 Revenue Up 21% to ₹1,422 Cr; PAT Rises 18% to ₹267 Cr
Ajanta Pharma reported a robust Q4 FY26 with revenue growing 21% YoY to ₹1,422 crore, driven by a massive 56% surge in US Generic sales. Despite a ₹42 crore mark-to-market forex loss, the company maintained a healthy PAT growth of 18% at ₹267 crore. For the full year FY26, revenue reached ₹5,453 crore with a PAT of ₹1,056 crore, marking a significant milestone. The company's India branded business continues to outperform the broader market, particularly in new launches and volumes.
Key Highlights
Q4 Revenue from operations grew 21% YoY to ₹1,422 cr; FY26 Revenue up 17% to ₹5,453 cr
Q4 PAT increased 18% to ₹267 cr; FY26 PAT crossed ₹1,000 cr mark, up 15% YoY
US Generic segment showed exceptional growth of 56% in Q4 and 49% for the full year
India branded business outperformed the Indian Pharma Market (IPM) growth by 33% as per IQVIA MAT March 2026
EBITDA margins for FY26 stood at 26%, despite a ₹103 cr mark-to-market forex loss impact
👀 What to Watch
Investors should note the strong momentum in the US and India markets, which are successfully offsetting weakness in the Asia segment. The company's high ROCE of 33% and consistent market outperformance suggest a strong fundamental position.
Ajanta Pharma Paithan Facility Receives 5 US FDA Observations
The US FDA conducted a routine inspection at Ajanta Pharma's manufacturing facility located in Paithan, Maharashtra, from April 13 to April 21, 2026. The audit concluded with the issuance of Form-483, containing 5 observations regarding the plant's compliance. The company has committed to responding to these observations within the stipulated regulatory timeline. Investors should note that the severity of these observations will determine the facility's future clearance status for US exports.
Key Highlights
Inspection conducted at the Paithan, Maharashtra facility between April 13 and April 21, 2026.
US FDA issued Form-483 with 5 observations following the conclusion of the audit.
Company is preparing a formal response to be submitted within the required regulatory timeframe.
The Paithan site is a significant manufacturing hub for Ajanta Pharma's international product portfolio.
👀 What to Watch
Investors should monitor for the US FDA's final classification of the inspection; a 'Voluntary Action Indicated' (VAI) would be manageable, while an 'Official Action Indicated' (OAI) could delay new product approvals.
Ajanta Pharma Denies ₹2,000 Cr Fundraise Rumours for Restaurant Brands Asia Acquisition
Ajanta Pharma Limited has officially denied news reports claiming it plans to raise ₹2,000 crore to acquire Restaurant Brands Asia (RBA). The company clarified that the acquisition is being pursued independently by a section of the promoter group through Lenexis Foodworks Pvt. Ltd., and not by the listed entity. This clarification addresses a report in The Economic Times which incorrectly suggested the drugmaker was diversifying into the Quick Service Restaurant (QSR) sector. The management confirmed that Ajanta Pharma Limited is in no way involved in this transaction.
Key Highlights
Company denies raising ₹2,000 crore for the acquisition of Restaurant Brands Asia.
Clarifies that the listed entity, Ajanta Pharma, is not a party to the QSR sector diversification.
The acquisition is an independent move by the promoter group via Lenexis Foodworks Pvt. Ltd.
This is a follow-up clarification to a similar denial issued by the company on January 20, 2026.
👀 What to Watch
Investors should ignore rumours regarding capital misallocation or unrelated diversification into the QSR sector. The core pharmaceutical business remains unaffected by the promoter group's private investment activities.
Ajanta Pharma Denies Rumours of Stake Acquisition in Restaurant Brands Asia
Ajanta Pharma Limited has officially denied media reports suggesting it was considering an acquisition of a stake in Restaurant Brands Asia (Burger King operator). The company clarified that neither the management nor the entity is involved in any discussions or negotiations regarding this transaction. This response follows a Reuters article dated January 19, 2026, which incorrectly linked the pharmaceutical firm to the Everstone stake sale. The company maintains that the rumors are baseless and it remains committed to its core operations.
Key Highlights
Ajanta Pharma issued a formal denial regarding the acquisition of any stake in Restaurant Brands Asia.
The clarification was made under Regulation 30(11) of SEBI Listing Obligations and Disclosure Requirements.
Management confirmed no discussions or proposals have been considered relating to the Burger King franchise.
The company labeled the news reports appearing in Reuters and Economic Times as incorrect.
Ajanta Pharma reaffirmed its adherence to high standards of corporate governance and timely disclosures.
👀 What to Watch
Investors should disregard the speculative news regarding the company's entry into the QSR space and focus on its pharmaceutical business fundamentals. No change in investment thesis is required based on this clarification.
Ajanta Pharma Incorporates New Wholly Owned Subsidiary in Ireland
Ajanta Pharma Limited has announced the incorporation of a new wholly owned subsidiary, Ajanta Pharma Ireland Ltd., based in Ireland. The new entity is established specifically to carry out the business of pharmaceutical products in the region. As a newly incorporated company, it currently has no turnover or historical financial data. This move signifies Ajanta Pharma's strategic intent to expand its operational footprint and market presence within the European pharmaceutical landscape.
Key Highlights
Incorporation of 'Ajanta Pharma Ireland Ltd.' as a 100% wholly owned subsidiary.
The subsidiary is established in Ireland to focus on the pharmaceutical products business.
The entity is a fresh incorporation with zero historical turnover or assets at this stage.
The move is compliant with Regulation 30 of the SEBI Listing Regulations.
Strategic expansion aimed at strengthening the company's international business operations.
👀 What to Watch
Investors should view this as a positive long-term strategic step for international growth. Monitor future quarterly updates for any capital infusion or revenue guidance related to the Irish operations.
Ajanta Pharma Partners with Biocon to Market Semaglutide in 26 Countries
Ajanta Pharma has entered an in-licensing agreement with Biocon to market Semaglutide, a high-growth GLP-1 therapy, across 26 countries in Africa, the Middle East, and Central Asia. The agreement provides Ajanta with exclusive marketing rights in 23 countries and semi-exclusive rights in 3 others. Commercialization is expected to commence in late 2026 or early 2027, following the expiry of product patents in March 2026. This move leverages Ajanta's existing infrastructure of over 2,000 medical representatives and 220+ brands in emerging markets.
Key Highlights
In-licensing agreement with Biocon for Semaglutide marketing in 26 emerging market countries.
Exclusive rights secured for 23 countries and semi-exclusive rights for 3 countries.
Commercial launch targeted for late 2026/early 2027 after patent expiry in March 2026.
Ajanta reported FY2024-25 Revenue of Rs. 4,648 cr and a healthy 3-year PAT CAGR of 25%.
Strategic entry into the blockbuster GLP-1 receptor agonist category to improve glycaemic control.
👀 What to Watch
Investors should view this as a significant long-term growth catalyst for Ajanta's branded generic business in emerging markets. Monitor regulatory approval progress in 2026 as a precursor to revenue contribution in 2027.
